PitchSend

Investor Presentaiton

31st January 2024 Our R&D continues to provide product innovation R&D Spend (Excluding Capex) (Rs. cr.) 9% 6% 5% 6% 6% 176 164 139 237 204 ■FY 2019 ■FY 2020 FY 2021 FY 2022 ■FY 2023 Q3 FY 2024 - Rs. 52 cr. (Rs. 61 cr.) 9M FY 2024 - Rs. 157 cr. (Rs. 174 cr.) 5% of Revenue • • • Strong Capabilities 800+ Scientists Formulation Development Analytical Development API Development Bio-Analytical Lab Drug Regulatory Affairs • IPR 23 ajanta

View entire presentation